How to assess anti-tumour efficacy by imaging techniques

European Journal of Cancer

Volumn 44, Issue 1, 2008, Pages 39-45

  Gwyther, Stephen J ^a   Schwartz, Lawrence H ^b  

^a EAST SURREY HOSPITAL   (United Kingdom)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cytocidal agents; Cytostatic agents; Dynamic contrast enhanced MRI and CT; PET CT; RECIST; Response evaluation; Volumetric studies

Indexed keywords

ANTINEOPLASTIC AGENT; CONTRAST MEDIUM; CYTOSTATIC AGENT; FLUORODEOXYGLUCOSE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD FLOW; BLOOD VOLUME; CANCER THERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DRUG EFFICACY; HUMAN; IMAGE ANALYSIS; IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME; VOLUMETRY;

CYTOSTATIC AGENTS; DRUG DESIGN; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 37149009994     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2007.10.010     Document Type: Article

References (18)

1. CPMP/EWP/205/95/Rev.3/Corr.2 Guideline on the evaluation of anticancer medicinal products in man. June 2006. [accessed 26.02.2007].
2. Millar A.B., Hoogstraten B., Staquet M., and Winkler A. Reporting results of cancer treatment. Cancer (Phila) 47 (1981) 207-214
3. Gwyther S.J., Aapro M.S., Hatty S.R., Postmus P.E., and Smith I.E. Independent review of gemcitabine in patients with non-small cell lung cancer (NSCLC). Eur Respirat J 10 25 (1997) 196s-197s
4. Gwyther S.J., Bolis G., ten Bokkel Huinink W., et al. Experience with independent radiological review during a topotecan trial in ovarian cancer. Annal Oncol 8 (1997) 463-467
5. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst (Bethesda) 92 (2000) 205-216
6. James K., Eisenhauer E.A., Christian M.C., et al. Measuring response in solid tumors: uni-dimensional versus bi-dimensional measurement. J Natl Cancer Inst (Bethesda) 91 (1999) 523-528
7. Dachman A.H., MacEneaney P.M., Adedipe A., Carlin M., and Schumm L.P. Tumor size on computed tomography scans: is one measurement enough?. Cancer (Phila) 91 (2001) 555-560
8. Kamiyoshihara M., Kawashima O., Ishikawa S., and Morishita Y. Mediastinal lymph node evaluation by computed tomographic scan in lung cancer. J Cardiovasc Surg (Torino) 42 (2001) 119-124
9. Konishi J., Yamazaki K., Tsukamoto E., et al. Mediastinal lymph node staging by FDG-PET in patients with non-small cell lung cancer: analysis of false-positive FDG-PET findings. Respiration 70 (2003) 500-506
10. Schwartz L.H., Colville J.A.C., Ginsberg M.S., et al. Measuring tumor response and shape change on CT: esophageal cancer as a paradigm. Annal Oncol 17 (2006) 1018-1023
11. Byrne M.J., and Nowak A.K. Modified RECIST criteria for assessment of response with malignant pleural mesothelioma. Annal Oncol 15 (2004) 257-260
12. Schwartz L.H., Mazumdar M., Brown W., Smith A., and Panicek D.M. Variability in response assessment in solid tumors: Effect of number of lesions chosen for measurement. Clin Cancer Res 9 (2003) 4318-4323
13. Kuhl C.K., Mielcareck P., Klaschik S., et al. Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions. Radiology 211 (1999) 101-110
14. Hahn OM, Yeng C, Medved M, et al. Dynamic contrast enhanced MRI (DCE-MRI) pharmacodynamic (PD) study of sorafenib in metastatic renal cell carcinoma (RCC): Results of a randomized phase II trial. In: JCO 2007; ASCO annual meeting proceedings (post-meeting edition); 25: No.18S (June 20 Suppl.); 2007. p. 3545.
15. Cheson B.D., Horning S.J., Coiffier B., et al. Report of an international workshop to standardize response criteria for Non-Hodgkin's lymphomas. J Clin Oncol 17 (1999) 1244-1253
16. Juweid M.E., Wiseman G.A., Vose J.M., et al. Response assessment of aggressive Non-Hodgkin's lymphoma by integrated international workshop criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol 23 (2005) 4652-4661
17. Juweid M.E., Stroobants S., Hoekstra O.S., et al. Use of positron emission tomography for response assessment in lymphoma: consensus of the imaging subcommittee of international harmonization project in lymphoma. J Clin Oncol 25 (2007) 571-578
18. Cheson B.D., Pfiestner B., Juweid M.E., et al. Revised response criteria for malignant lymphoma. J Clin Oncol 25 (2007) 579-586